Back to Search Start Over

β-arrestin2: an emerging player and potential therapeutic target in inflammatory immune diseases.

Authors :
Gao PP
Li L
Chen TT
Li N
Li MQ
Zhang HJ
Chen YN
Zhang SH
Wei W
Sun WY
Source :
Acta pharmacologica Sinica [Acta Pharmacol Sin] 2024 Sep 30. Date of Electronic Publication: 2024 Sep 30.
Publication Year :
2024
Publisher :
Ahead of Print

Abstract

β-arrestin2, a pivotal protein within the arrestin family, is localized in the cytoplasm, plasma membrane and nucleus, and regulates G protein-coupled receptors (GPCRs) signaling. Recent evidence shows that β-arrestin2 plays a dual role in regulating GPCRs by mediating desensitization and internalization, and by acting as a scaffold for the internalization, kinase activation, and the modulation of various signaling pathways, including NF-κB, MAPK, and TGF-β pathways of non-GPCRs. Earlier studies have identified that β-arrestin2 is essential in regulating immune cell infiltration, inflammatory factor release, and inflammatory cell proliferation. Evidently, β-arrestin2 is integral to the pathological mechanisms of inflammatory immune diseases, such as inflammatory bowel disease, sepsis, asthma, rheumatoid arthritis, organ fibrosis, and tumors. Research on the modulation of β-arrestin2 offers a promising strategy for the development of pharmaceuticals targeting inflammatory immune diseases. This review meticulously describes the roles of β-arrestin2 in cells associated with inflammatory immune responses and explores its pathological relevance in various inflammatory immune diseases.<br /> (© 2024. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society.)

Details

Language :
English
ISSN :
1745-7254
Database :
MEDLINE
Journal :
Acta pharmacologica Sinica
Publication Type :
Academic Journal
Accession number :
39349766
Full Text :
https://doi.org/10.1038/s41401-024-01390-w